Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 18.47 USD -0.48% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Travere Therapeutics Inc?
Write Note

Travere Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Travere Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Travere Therapeutics Inc
NASDAQ:TVTX
Operating Income
-$279.7m
CAGR 3-Years
-6%
CAGR 5-Years
-25%
CAGR 10-Years
-14%
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%

See Also

What is Travere Therapeutics Inc's Operating Income?
Operating Income
-279.7m USD

Based on the financial report for Sep 30, 2024, Travere Therapeutics Inc's Operating Income amounts to -279.7m USD.

What is Travere Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-14%

Over the last year, the Operating Income growth was 22%. The average annual Operating Income growth rates for Travere Therapeutics Inc have been -6% over the past three years , -25% over the past five years , and -14% over the past ten years .

Back to Top